Monitoring of patients treated with interferons

Interferon alpha (IFN-alpha) and interferon beta (IFN-beta) have been used for treating many disorders with widespread clinical effects. However, like many other proteins, all IFN species are potentially immunogenic, particularly those produced by recombinant gene technology. The reported frequencies and titers of anti-IFN antibodies varies significantly depending on various diseases, IFN preparations and administration, and the type of method used for detection of antibodies. Antibody-mediated decreased bioactivity of IFN (ADB) is increasingly recognised as a condition in which the clinical effect of prolonged continuous treatment with IFN is decreased or abolished. Wieslab has chosen to use a method that measures neutralizing antibodies (NAbs) against biological active interferon which is considered therapeutic significant.

Read more on the following pages:

IFN-alpha treatment

IFN-beta treatment

Immunogenicity

Assay principle

Sampling instructions

Traditional methods

Suggested literature

Order of test: Print and complete the Monitoring of biopharmaceuticals request form and send it together with the sample.

Read more about sampling.

For further questions please contact us.

To receive more information about drug monitoring please visit www.eurodiagnostica.com.

Own immunologist